Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems

Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.